Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders

• US 20070212337A1
• Filed: 01/31/2007
• Published: 09/13/2007
• Est. Priority Date: 02/01/2006
• Status: Abandoned Application

• Current Assignee: Johns Hopkins University, Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Original Assignee: Johns Hopkins University
• Inventors: Ravi, Rajani, Bedi, Atul, Li, Shulin
• Application Number:
  US11/701,092
• Publication Number:
  US 20070212337A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/6025 Nucleotides
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001102 Receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: A61K 39/001103 Receptors for growth factors
• CPC Class Codes: A61K 39/001104 Epidermal growth factor receptors [EGFR]
• CPC Class Codes: A61K 39/001106 Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
• CPC Class Codes: A61K 39/001107 Fibroblast growth factor receptors [FGFR]
• CPC Class Codes: A61K 39/001108 Platelet-derived growth factor receptors [PDGFR]
• CPC Class Codes: A61K 39/001109 Vascular endothelial growth factor receptors [VEGFR]
• CPC Class Codes: A61K 39/001122 Ephrin Receptors [Eph]
• CPC Class Codes: A61K 39/001124 CD20
• CPC Class Codes: A61K 39/001136 Cytokines
• CPC Class Codes: A61K 39/001138 Tumor necrosis factors [TNF] or CD70
• CPC Class Codes: A61K 39/001141 Interferons [IFN]
• CPC Class Codes: A61K 39/001153 Wilms tumor 1 [WT1]
• CPC Class Codes: A61K 39/001156 Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
• CPC Class Codes: A61K 39/001159 Matrix metalloproteinases [MMP]
• CPC Class Codes: A61K 39/001161 Caspases
• CPC Class Codes: A61K 39/001162 Kinases, e.g. Raf or Src
• CPC Class Codes: A61K 39/001166 : Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
• CPC Class Codes: A61K 39/00117 : Mucins, e.g. MUC-1
• CPC Class Codes: A61K 39/001171 : Gangliosides, e.g. GM2, GD2 or GD3
• CPC Class Codes: A61K 39/001182 : Carcinoembryonic antigen [CEA]
• CPC Class Codes: A61K 39/001184 : Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
• CPC Class Codes: A61K 39/001186 : MAGE
• CPC Class Codes: A61K 39/001193 : Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
• CPC Class Codes: A61K 39/001194 : Prostate specific antigen [PSA]
• CPC Class Codes: A61K 39/001195 : Prostate specific membrane antigen [PSMA]
• CPC Class Codes: A61K 39/001197 : Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: C07K 16/2863 : against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/32 : against translation products of oncogenes
• CPC Class Codes: C07K 2317/73 : Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/74 : Inducing cell proliferation
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody/peptide-nucleic acid conjugate. The conjugate is able to simultaneously activate multiple death signaling mechanisms that are specifically targeted to neoplastic cells, including tumor cells. Methods of using the conjugate of the present invention as an immunotherapeutic modality for the treatment or prevention of neoplastic diseases or other disorders is also disclosed. Further, methods are disclosed for identifying such conjugates by assaying test agents for various cytotoxic responses, including the induction of hyperfusion between neoplastic cells in vitro.

Claims

1. An isolated antibody-nucleic acid or peptide-nucleic acid conjugate comprising:

i) an antibody or peptide that specifically binds to a cellular component of;

a) a tumor cell;

b) tumor vasculature; and

/or

c) a component of a tumor microenvironment; and

ii) one or more immunostimulatory nucleic acid sequences (INAS), wherein one or more of the nucleic acid sequences comprise a pathogen-associated molecular pattern (PAMP).

2. The conjugate of claim 1, wherein the antibody is selected from the group consisting of a multispecific antibody, a human antibody, a humanized antibody, a chimeric antibody, a single chain antibody, an Fab fragment, an F(ab′

) fragment, and an anti-idiotypic (anti-Id) antibody.

3. The conjugate of claim 1, wherein the cellular component is a tumor associated antigen or cell surface molecule.

4. The conjugate of claim 1, wherein the cellular component is selected from the group consisting of growth-factor receptors, co-stimulatory molecules, hormone receptors, cytokine receptors.

5. The conjugate of claim 1, wherein the cellular component is selected from the group consisting of epidermal growth factor receptor (EGFR, ErbB-1, HER1), ErbB-2 (HER2/neu), ErbB-3/HER3, ErbB-4/HER4, EGFR ligand family;

insulin-like growth factor receptor (IGFR) family, IGF-binding proteins (IGFBPs), IGFR ligand family;

platelet derived growth factor receptor (PDGFR) family, PDGFR ligand family;

fibroblast growth factor receptor (FGFR) family, FGFR ligand family, vascular endothelial growth factor receptor (VEGFR) family, VEGF family;

HGF receptor family;

TRK receptor family;

ephrin (EPH) receptor family;

AXL receptor family;

leukocyte tyrosine kinase (LTK) receptor family;

TIE receptor family, angiopoietin 1,2;

receptor tyrosine kinase-like orphan receptor (ROR) receptor family;

discoidin domain receptor (DDR) family;

RET receptor family;

KLG receptor family;

RYK receptor family;

MuSK receptor family;

Transforming growth factor β

(TGF-β

) receptors, TGF-β

;

Cytokine receptors, Class I (hematopoietin family) and Class II (interferon/IL-10 family) receptors, tumor necrosis factor (TNF) receptor superfamily (TNFRSF), death receptor family;

cancer-testis (CT) antigens, lineage-specific antigens, differentiation antigens, alpha-actinin-4, ARTC1, breakpoint cluster region-Abelson (Bcr-abl) fusion products, B-RAF, caspase-5 (CASP-5), caspase-8 (CASP-8), β

-catenin (CTNNB1), cell division cycle 27 (CDC27), cyclin-dependent kinase 4 (CDK4), CDKN2A, COA-1, dek-can fusion protein, EFTUD-2, Elongation factor 2 (ELF2), Ets variant gene 6/acute myeloid leukemia 1 gene ETS (ETC6-AML1) fusion protein, fibronectin (FN), GPNMB, low density lipid receptor/GDP-L fucose;

β

-Dgalactose 2-α

-Lfucosyltransferase (LDLR/FUT) fusion protein, HLA-A2. arginine to isoleucine exchange at residue 170 of the α

-helix of the α

2-domain in the HLA-A2 gene (HLA-A*201-R170I), HLA-A11, heat shock protein 70-2 mutated (HSP70-2M), KIAA0205, MART2, melanoma ubiquitous mutated 1, 2, 3 (MUM-1, 2,

     3), prostatic acid phosphatase (PAP), neo-PAP, Myosin class I, NFYC, OGT, OS-9, pml-RARalpha fusion protein, PRDX5, PTPRK, K-ras (KRAS2), N-ras (NRAS), HRAS, RBAF600, SIRT2, SNRPD1, SYT-SSX1 or —

SSX2 fusion protein, Triosephosphate Isomerase, BAGE, BAGE-1, BAGE-2,3,4,5, GAGE-1,2,3,4,5,6,7,8, GnT-V (aberrant N-acetyl glucosaminyl transferase V, MGAT5), HERV-K-MEL, KK-LC, KM-HN-1, LAGE, LAGE-1, CTL-recognized antigen on melanoma (CAMEL), MAGE-A1 (MAGE-1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-3, MAGE-B1, MAGE-B2, MAGE-B5, MAGE-B6, MAGE-C1, MAGE-C2, mucin 1 (MUC1), MART-1/Melan-A (MLANA), gp100, gp100/Pmel17 (SILV), tyrosinase (TYR), TRP-1, HAGE, NA-88, NY-ESO-1, NY-ESO-1/LAGE-2, SAGE, Sp17, SSX-1,2,3,4, TRP2-INT2, carcino-embryonic antigen (CEA), Kallikrein 4, mammaglobin-A, OA1, prostate specific antigen (PSA), TRP-1/gp75, TRP-2, adipophilin, interferon inducible protein absent in melanoma 2 (AIM-2), BING-4, CPSF, cyclin D1, epithelial cell adhesion molecule (Ep-CAM), EphA3, fibroblast growth factor-5 (FGF-5), glycoprotein 250 (gp250), EGFR (ERBB1), HER-2/neu (ERBB2), interleukin 13 receptor α

2 chain (IL13Ralpha2), IL-6 receptor, intestinal carboxyl esterase (iCE), alpha-feto protein (AFP), M-CSF, mdm-2, MUC1, p53 (TP53), PBF, PRAME, PSMA, RAGE-1, RNF43, RU2AS, SOX10, STEAP1, survivin (BIRC5), human telomerase reverse transcriptase (hTERT), telomerase, Wilms'"'"' tumor gene (WT1), SYCP1, BRDT, SPANX, XAGE, ADAM2, PAGE-5, LIP1, CTAGE-1, CSAGE, MMA1, CAGE, BORIS, HOM-TES-85, AF15q14, HCA661, LDHC, MORC, SGY-1, SPO11, TPX1, NY-SAR-35, FTHL17, NXF2, TDRD1, TEX15, FATE, TPTE, immunoglobulin idiotypes, Bence-Jones protein, estrogen receptors (ER), androgen receptors (AR), CD40, CD30, CD20, CD19, CD33, cancer antigen 72-4 (CA 72-4), cancer antigen 15-3 (CA 15-3), cancer antigen 27-29 (CA 27-29), cancer antigen 125 (CA

     125), cancer antigen 19-9 (CA 19-9), β

-human chorionic gonadotropin, squamous cell carcinoma antigen, neuron-specific enolase, heat shock protein gp96, GM2, sargramostim, CTLA-4, 707 alanine proline (707-AP), adenocarcinoma antigen recognized by T cells 4 (ART-4), carcinoembryogenic antigen peptide-1 (CAP-1), calcium-activated chloride channel-2 (CLCA2), cyclophilin B (Cyp-B), human signet ring tumor-2 (HST-2), Human papilloma virus (HPV) proteins (HPV-E6, HPV-E7, major or minor capsid antigens, others), Epstein-Barr virus (EBV) proteins (EBV latent membrane proteins—

LMP1, LMP2;

others), Hepatitis B or C virus proteins, and HIV proteins.

6. The conjugate of claim 5, wherein the cellular component is EGFR or HER2/neu.

7. The conjugate of claim 3, wherein the peptide is selected from the group consisting of α

vβ

1 integrin (CRRETAWAC (SEQ ID NO;

5)), α

vβ

3 integrin (CDCRGDCFC (SEQ ID NO;

6)/RGD-4C;

RGDWXE (SEQ ID NO;

7)), α

vβ

5 integrin (TRGDTF (SEQ ID NO;

8)), α

vβ

6 (RGDLxxL (SEQ ID NO;

9) or xxDLxxL (SEQ ID NO;

10)), α

IIβ

3 (SRGDM (SEQ ID NO;

11)), annexin V mimic for α

vβ

5 (VVISYSMPD (SEQ ID NO;

12)), E-selectin (IELLQAR (SEQ ID NO;

13)), Endothelial cell mitochondria (CNGRC-GG-(KLAKLAK)2 (SEQ ID NO;

14)), Ephrin-A2 and Ephrin-A4 (CVSNPRWKC (SEQ ID NO;

15), CHVLWSTRC (SEQ ID NO;

16)), Fibronectin (CWDDGWLC (SEQ ID NO;

17)), ICAM-I or von Willebrand factor (CPCFLLGCC (SEQ ID NO;

18)/LLG-4C), lamin-1 (DFKLFAVY (SEQ ID NO;

19)), P-selectin (EWVDV (SEQ ID NO;

20)), MMP-9;

integrin complex (D/E)(D/E)(G/L)W (SEQ ID NO;

21), MMP-9 and MMP-2 (gelatinases) (CTTHWGFTLC (SEQ ID NO;

22)), Type I cadherin on endothelium (N-Ac-CHAVC-NH2), Flt-1 region of VEGF NxxEIExYxxWxxxxxY(SEQ ID NO;

23), KDR region of VEGF (HTMYYHHYQHHL (SEQ ID NO;

24), ATWLPPR(SEQ ID NO;

25)), VEGF receptor (WHSDMEWWYLLG (SEQ ID NO;

26), RRKRRR (SEQ ID NO;

27), Aminopeptidase N/CD13 (NGR), NG2 proteolgycan (TAASGVRSMH (SEQ ID NO;

28), LTLRWVGLMS (SEQ ID NO;

29)), Adrenal gland derived peptide (LMLPRAD (SEQ ID NO;

30)), Adipose Tissue derived peptide (CKGGRAKDC SEQ ID NO;

31)), Brain derived peptide (SR1), Brain endothelium derived peptide (CLSSRLDAC (SEQ ID NO;

32)), Glioma cell derived peptide (VGLPEHTQ (SEQ ID NO;

33)), Neuroblastoma derived peptide (VPWMEPAYQRFL (SEQ ID NO;

34)), Bone Marrow derived peptide (GGG, GFS, LWS), Breast cancer (HER2/neu) derived peptide (LTVxPWx (SEQ ID NO;

35), LTVxPWY (SEQ ID NO;

36), HER2 Ab/Trastuzumab mimotope—

LLGPYELWELSH (SEQ ID NO;

37)), Colon derived peptide (RPMC (SEQ ID NO;

38)), Intestine derived peptide (YSGKWGW (SEQ ID NO;

39)), Head and Neck Squamous Cell Cancer derived peptide (TSPLNIHNGQKL (SEQ ID NO;

40)), Lung vasculature derived peptide (CGFELETC(SEQ ID NO;

41)), Coronary artery endothelia derived peptide (NSVRDL(G/S) (SEQ ID NO;

42), NSVSSx(S/A) (SEQ ID NO;

43)), Lymphatic Vessel derived peptide (CGNKRTRGC (SEQ ID NO;

44)/Lyp-1), Multiple Organ derived peptide (GVL, EGRx (SEQ ID NO;

45), xFG(GN) (SEQ ID NO;

46)), Pancreatic Islet derived peptide (CVSSNPRWKC (SEQ ID NO;

47), CHVLWSTRC (SEQ ID NO;

48)), Pancreas derived peptide (SWCEPGWCR (SEQ ID NO;

49)), Prostate derived peptide (AGG, DPRATPGS (SEQ ID NO;

50), SMSIARL (SEQ ID NO;

51), CGRRAGGSC (SEQ ID NO;

52), GVL), Retina derived peptide (RDVI CSCFRDVCC (SEQ ID NO;

53)), Teratogen ligand derived peptide (TPKTSVT (SEQ ID NO;

54)), and Uterus derived peptide (GLSGGRS (SEQ ID NO;

55)).

8. The conjugate of claim 1, wherein the INAS comprises a coding or non-coding nucleic acid.

9. The conjugate of claim 8, wherein the non-coding sequence is selected from the group consisting of double stranded DNA, single stranded DNA, CpG DNA (CpG), herpes simplex virus (HSV) DNA, double stranded RNA (dsRNA), CpG DNA (CpG), and single stranded RNA (ssRNA).

10. The conjugate of claim 9, wherein the non-coding sequence is CpG.

11. The conjugate of claim 10, wherein the CpG comprises SEQ ID NO:

1.

12. The conjugate of claim 1, comprising:

i) an antibody that specifically binds to EGFR or HER/neu; and

ii) one or more immunostimulatory nucleic acid sequences, wherein

one or more of the nucleic acid sequences comprise a CpG DNA-sequence as set forth in SEQ ID NO;

1.

13. The conjugate of claim 1, comprising:

i) a peptide containing an RGD motif or a CDGRC motif; and

ii) one or more immunostimulatory nucleic acid sequences, wherein

one or more of the nucleic acid sequences comprise a CpG DNA sequence as set forth in SEQ ID NO;

1.

14. A method of treating a neoplastic disease comprising administering to a subject in need thereof, a composition comprising an antibody-nucleic acid conjugate or a peptide-nucleic acid conjugate, wherein the conjugate comprises:

i) an antibody or a peptide that specifically binds to a cellular component of;

a) a tumor cell,

b) tumor vasculature, and/or

c) a component of a tumor microenvironment; and

ii) one or more immunostimulatory nucleic acid sequences, wherein

one or more of the nucleic acid sequences comprise a pathogen-associated molecular pattern (PAMP).

15. The method of claim 14, wherein the conjugate is administered systemically, intratumorally, or peritumorally.

16. The method of claim 14, further comprising:

i) removing immune cells from the subject;

ii) contacting the cells of step (i) with the conjugate ex vivo; and

iii) reintroducing the cells of step (ii) into the subject.

17. The method of claim 14, further comprising administering an anticancer therapy selected from the group consisting of ionizing radiation, hormonal therapy, cytokines, immunotherapy, cellular therapy, vaccines, monoclonal antibodies, anti-angiogenic agents, and small molecule chemotherapeutic drugs.

18. The method of claim 14, wherein one or more of the nucleic acid sequences silences gene expression or induces intracellular death signaling.

19. The method of claim 18, wherein one or more of the nucleic acid sequences is double stranded RNA (dsRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), or micro RNA.

20. The method of claim 18, wherein at least one nucleic acid sequence encodes a peptide, a polypeptide, or a protein.

21. The method of claim 14, wherein the cellular component is selected from the group consisting of epidermal growth factor receptor (EGFR), HER2/neu, insulin-like growth factor receptor family, platelet derived growth factor receptor, interleukin-6 receptor, vascular endothelial growth factor (VEGF), VEGF receptor, CD40, CD28, estrogen receptors, cytokine receptors, CD20, CD19, CD33, MART-1/Melan-A, gp100, tyrosinase, TRP-1, MAGE-1, MAGE-3, MAGE-B1, MAGE-B2, BAGE, BAGE-1, GAGE-2, HAGE, LAGE, melanoma ubiquitous mutated 1, 2, 3 (MUM-1, 2, 3), β

-catenin, carcino-embryonic antigen (CEA), HPV-E6, HPV-E7, mucin 1, prostate specific antigen (PSA), Epstein-Barr virus, alpha-feto protein (AFP), cancer antigen 72-4 (CA 72-4), cancer antigen 15-3 (CA 15-3), cancer antigen 27-29 (CA 27-29), cancer antigen 125 (CA

     125), cancer antigen 19-9 (CA 19-9), β

-human chorionic gonadotropin, squamous cell carcinoma antigen, Bence-Jones protein, neuron-specific enolase, heat shock protein gp96, heat shock protein 70-2 mutated (HSP70-2M), GM2, sargramostim, CTLA-4, prostatic acid phosphatase (PAP), NY-ESO-1, 707 alanine proline (707-AP), interferon inducible protein absent in melanoma 2 (AIM-2), adenocarcinoma antigen recognized by T cells 4 (ART-4), breakpoint cluster region-Abelson (Bcr-abl), CTL-recognized antigen on melanoma (CAMEL), carcinoembryogenic antigen peptide-1 (CAP-1), caspase-8 (CASP-8), cell division cycle 27 (CDC27), cyclin-dependent kinase 4 (CDK4), calcium-activated chloride channel-2 (CLCA2), cancer/testis antigen (CT), cyclophilin B (Cyp-B), elongation factor 2 (ELF2), epithelial cell adhesion molecule (Ep-CAM), ephrin type-A receptor 2, 3 (EphA2,

     3), Ets variant gene 6/acute myeloid leukemia 1 gene ETS (ETC6-AML1), fibroblast growth factor 5 (FGF-5) fibronectin (FN), glycoprotein 250 (gp250), N-acetylglucosaminyltransferase V (GnT-V), arginine to isoleucine exchange at residue 170 of the α

-helix of the α

2-domain in the HLA-A2 gene (HLA-A*201-R170I), human signet ring tumor-2 (HST-2) human telomerase reverse transcriptase (hTERT), intestinal carboxyl esterase (iCE), interleukin 13 receptor α

2 chain (IL-13Rα

2), KIAA0205, low density lipid receptor/GDP-L fucose;

β

-Dgalactose 2-α

-Lfucosyltransferase (LDLR/FUT), and Wilms'"'"' tumor gene (WT1).

22. The method of claim 14, wherein the conjugate comprises an antibody that specifically binds to EGFR or HER2/neu and one or more immunostimulatory nucleic acid sequences, wherein the one or more of the nucleic acid sequences comprise a CpG DNA sequence as set forth in SEQ ID NO:

1.

23. The method of claim 14, wherein the peptide is selected from the group consisting of α

vβ

1 integrin (CRRETAWAC (SEQ ID NO;

5)), α

vβ

3 integrin (CDCRGDCFC (SEQ ID NO;

6)/RGD-4C;

RGDWXE (SEQ ID NO;

7)), α

vβ

5 integrin (TRGDTF (SEQ ID NO;

8)), α

vβ

6 (RGDLxxL (SEQ ID NO;

9) or xxDLxxL (SEQ ID NO;

10)), α

IIβ

3 (SRGDM (SEQ ID NO;

11)), annexin V mimic for α

vβ

5 (VVISYSMPD (SEQ ID NO;

12)), E-selectin (IELLQAR (SEQ ID NO;

13)), Endothelial cell mitochondria (CNGRC-GG-(KLAKLAK)2 (SEQ ID NO;

14)), Ephrin-A2 and Ephrin-A4 (CVSNPRWKC (SEQ ID NO;

15), CHVLWSTRC (SEQ ID NO;

16)), Fibronectin (CWDDGWLC (SEQ ID NO;

17)), ICAM-I or von Willebrand factor (CPCFLLGCC (SEQ ID NO;

18)/LLG-4C), lamin-1 (DFKLFAVY (SEQ ID NO;

19)), P-selectin (EWVDV (SEQ ID NO;

20)), MMP-9;

integrin complex (D/E)(D/E)(Q/L)W (SEQ ID NO;

2

     1), MMP-9 and MMP-2 (gelatinases) (CTTHWGFTLC (SEQ ID NO;

22)), Type I cadherin on endothelium (N-Ac-CHAVC-NH2), Flt-1 region of VEGF NxxEIExYxxWxxxxxY(SEQ ID NO;

23), KDR region of VEGF (HTMYYHHYQHHL (SEQ ID NO;

24), ATWLPPR(SEQ ID NO;

25)), VEGF receptor (WHSDMEWWYLLG (SEQ ID NO;

26), RRKRRR (SEQ ID NO;

27), Aminopeptidase N/CD13 (NGR), NG2 proteolgycan (TAASGVRSMH (SEQ ID NO;

28), LTLRWVGLMS (SEQ ID NO;

29)), Adrenal gland derived peptide (LMLPRAD (SEQ ID NO;

30)), Adipose Tissue derived peptide (CKGGRAKDC SEQ ID NO;

31)), Brain derived peptide (SR1), Brain endothelium derived peptide (CLSSRLDAC (SEQ ID NO;

32)), Glioma cell derived peptide (VGLPEHTQ (SEQ ID NO;

33)), Neuroblastoma derived peptide (VPWMEPAYQRFL (SEQ ID NO;

34)), Bone Marrow derived peptide (GGG, GFS, LWS), Breast cancer (HER2/neu) derived peptide (LTVxPWx (SEQ ID NO;

35), LTVxPWY (SEQ ID NO;

36), HER2 Ab/Trastuzumab mimotope—

LLGPYELWELSH (SEQ ID NO;

37)), Colon derived peptide (RPMC (SEQ ID NO;

38)), Intestine derived peptide (YSGKWGW (SEQ ID NO;

39)), Head and Neck Squamous Cell Cancer derived peptide (TSPLNIHNGQKL (SEQ ID NO;

40)), Lung vasculature derived peptide (CGFELETC(SEQ ID NO;

41)), Coronary artery endothelia derived peptide (NSVRDL(G/S) (SEQ ID NO;

42), NSVSSx(S/A) (SEQ ID NO;

43)), Lymphatic Vessel derived peptide (CGNKRTRGC (SEQ ID NO;

44)/Lyp-1), Multiple Organ derived peptide (GVL, EGRx (SEQ ID NO;

45), xFG(GN) (SEQ ID NO;

46)), Pancreatic Islet derived peptide (CVSSNPRWKC (SEQ ID NO;

47), CHVLWSTRC (SEQ ID NO;

48)), Pancreas derived peptide (SWCEPGWCR (SEQ ID NO;

49)), Prostate derived peptide (AGG, DPRATPGS (SEQ ID NO;

50), SMSIARL (SEQ ID NO;

5

     1), CGRRAGGSC (SEQ ID NO;

52), GVL), Retina derived peptide (RDV, CSCFRDVCC (SEQ ID NO;

53)), Teratogen ligand derived peptide (TPKTSVT (SEQ ID NO;

54)), and Uterus derived peptide (GLSGGRS (SEQ ID NO;

55)).

24. The method of claim 14, wherein the conjugate comprises a peptide containing an RGD motif or a CDGRC motif and one or more immunostimulatory nucleic acid sequences, wherein the one or more of the nucleic acid sequences comprise a CpG DNA sequence as set forth in SEQ ID NO:

1.

25. The method of claim 14, wherein the neoplastic disease is cancer.

26. The method of claim 25, wherein the cancer is selected from the group consisting of head and neck cancers, aero-digestive cancers, gastro-intestinal cancers, esophageal cancers, stomach/gastric cancers, pancreatic cancers, hepato-biliary/liver cancers, colorectal cancers, anal cancers, small intestine cancers, genito-urinary cancers, urologic cancers, renal/kidney cancers, ureter cancers, testicular cancers, urethra/penis cancers, gynecologic cancers, ovarian/fallopian tube cancers, peritoneal cancers, uterine/endometrial cancers, cervical/vagina/vulva cancers, gestational trophoblastic disease, prostate cancers, bone cancers, sarcoma (soft tissue/bone), lung cancers, mesothelioma, mediastinum cancers, breast cancers, central nervous system cancers, brain cancers, melanoma, leukemia, lymphoma (Hodgkin'"'"'s Disease and Non-Hodgkin'"'"'s lymphoma), plasma cell neoplasms, myeloma, myelodysplastic syndrome, endocrine tumors, skin cancers, melanoma, thyroid cancers, parathyroid cancers, adrenal, pancreatic endocrine cancers, carcinoid, multiple endocrine neoplasia, AIDS-related malignancies, Cancer of unknown primary site, and various childhood cancers.

27. The method of claim 14, wherein the subject is a human.

28. A method of identifying a nucleic acid conjugate which induces cell death, cell maturation, and/or NKG2D ligand dependent signaling comprising:

i) contacting one or more cells in vitro with a test nucleic acid conjugate containing an antibody that specifically binds to a cellular component of a tumor cell, tumor vasculature, and/or a component of a tumor microenvironment or an integrin derived peptide containing an RGD motif or a CDGRC motif, wherein the antibody or peptide is conjugated toga nucleic acid comprising one or more immunostimulatory nucleic acid sequences, and wherein one or more of the nucleic acid sequences comprise a pathogen-associated molecular pattern (PAMP); and

ii) determining induction of a marker or a phenotypic change in the one or more cells of step (i) in the presence or absence of immune cells,

wherein the determined induction or change in the presence of the test nucleic acid conjugate in one or more cells of step (i) is indicative of cell death signaling, cell maturation, and/or NKG2D ligand dependent signaling.

29. The method of claim 28, wherein if the cells in step (i) are tumor cells, and in the absence immune cells, the contacting causes the cells to fuse, the test nucleic conjugate is associated with the induction of cell death signaling.

30. The method of claim 28, wherein if the cells in step (i) comprise a mixture of immune cells and tumor cells, and the contacting causes the tumor cells to lyse, the test nucleic conjugate is associated is associated with the induction of cell maturation and/or NKG2D ligand dependent signaling.

31. The method of claim 28, wherein if the cells in step (i) are PBMC cells or dendritic cells (DC), and the contacting causes the expression of one or more markers selected from the group consisting of CD86, IFN-γ

, and/or Apo2L/TRAIL, the test nucleic-acid conjugate is associated with the induction of cell maturation.

32. A method of preventing or treating a neoplastic disease or infectious disease comprising administering to a subject in need thereof, a composition comprising an antibody-nucleic acid conjugate, wherein the conjugate comprises:

i) an antibody that specifically binds to a cellular component of an immune cell or a dendritic cell (DC);

ii) one or more immunostimulatory nucleic acid sequences (INAS), wherein

one or more of the nucleic acid sequences comprise a pathogen-associated molecular pattern (PAMP); and

iii) one or more tumor antigens or antigens from an infectious or pathogenic microorganism.

33. The method of claim 32, further comprising:

i) removing immune cells from the subject;

ii) contacting the cells of step (i) with the conjugate ex vivo; and

iii) reintroducing the cells of step (ii) into the subject.

34. The method of claim 32, further comprising administering an anticancer therapy selected from the group consisting of ionizing radiation, hormonal therapy, cytokines, immunotherapy, cellular therapy, vaccines, monoclonal antibodies, anti-angiogenic agents, and small molecule chemotherapeutic drugs.

35. The method of claim 32, wherein the infectious disease is caused by an infection selected from the group consisting of a microbial infection, fungal infection, parasitic infection, and viral infection.

36. The method of claim 32, wherein the subject is a human.